Head-To-Head Comparison: Smith & Nephew (NYSE:SNN) and Bone Biologics (NASDAQ:BBLG)

Bone Biologics (NASDAQ:BBLG) and Smith & Nephew (NYSE:SNN) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations and valuation.

Profitability

This table compares Bone Biologics and Smith & Nephew’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bone Biologics	N/A	-151.99%	-121.03%
Smith & Nephew	N/A	N/A	N/A

Valuation and Earnings

This table compares Bone Biologics and Smith & Nephew’s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bone Biologics	N/A	N/A	-$8.95 million	N/A	N/A
Smith & Nephew	$5.55 billion	2.22	$263.00 million	N/A	N/A

Smith & Nephew has higher revenue and earnings than Bone Biologics.

Risk and Volatility

Bone Biologics has a beta of 0.31, meaning that its share price is 69% less volatile than the S&P 500. Comparatively, Smith & Nephew has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Bone Biologics and Smith & Nephew, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bone Biologics	0	0	0	0	N/A
Smith & Nephew	0	2	3	0	2.60

Institutional and Insider Ownership

34.3% of Bone Biologics shares are owned by institutional investors. Comparatively, 25.6% of Smith & Nephew shares are owned by institutional investors. 13.0% of Bone Biologics shares are owned by insiders. Comparatively, 1.0% of Smith & Nephew shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Smith & Nephew beats Bone Biologics on 6 of the 8 factors compared between the two stocks.

About Bone Biologics

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.